Endocrine Abstracts

Introduction: Transsphenoidal surgery (TSS) is the first-choice treatment in Cushing’s disease (CD) with an immediate success rate of 70-80%. Unfortunately, due to the high rate of post-operative recurrences, CD patients require life-long surveillance. However, there is no consensus on how to follow these patients after TSS to early diagnose relapses. The aim of the study was to find reliable predictors of recurrence after neurosurgery in CD.Materia...

Context: Cushing’s disease (CD) is rare condition burdened by several systemic complications that in turn increase mortality. The main goal of CD treatment is to promptly reduce cortisol excess, but whether remission can revert cortisol-related complications and guarantee a normal life expectancy remains debated. Aim: To assess the prevalence of cortisol-related complications and mortality in a large monocentric cohort of CD patients followed at our...

Introduction: Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by the high incidence of diabetes mellitus (DM). We aimed to evaluate the effect of a single subcutaneous injection of PAS on glucose metabolism in CD patients, to identify factors predicting rapid deterioration of glycaemic control.Methods: 14 patients [(f/m=12/2, mean age 43±11.3 years, follow-up 17 months (2-63)] with CD treated with ...

Introduction: Transsphenoidal surgery (TSS) is the first-choice treatment in Cushing’s disease (CD). When performed by experienced neurosurgeon, post-operative remission can be achieved in 70–80% of cases; however, recurrences during follow-up are quite frequent, involving around 20–30% of patients initially in remission. Early detection of relapses is crucial to avoid cortisol-related comorbidities. The aim of the study was to find reliable predictors of rec...